ROADMAP Randomised Olmesartan and Diabetes Microalbuminuria Prevention Study, created in 2004 (Japan), from 223 sister brands and 17477 competing brands. The ROADMAP Randomised Olmesartan and Diabetes Microalbuminuria Prevention Study brand is owned by Daiichi Sankyo, a company listed in Francfort. The International Securities Identification Number (ISIN) of Daiichi Sankyo is JP3475350009. The sector of ROADMAP Randomised Olmesartan and Diabetes Microalbuminuria Prevention Study is Drug Manufacturers.

ROADMAP Randomised Olmesartan and Diabetes Microalbuminuria Prevention Study is a brand of Daiichi Sankyo (D4S) Share price

Share price and profitability of the share Daiichi Sankyo (ROADMAP Randomised Olmesartan and Diabetes Microalbuminuria Prevention Study)

Buy Daiichi Sankyo share with
(0% commission and fractional shares)
Your capital is subject to risk. Other fees apply. For more information, visit etoro.com/trading/fees.

Investment simulator :

Amount invested EUR 32.36

Portfolio valuation
Daiichi Sankyo (ROADMAP Randomised Olmesartan and Diabetes Microalbuminuria Prevention Study) over 5 years* EUR 71.55

Stock market history Daiichi Sankyo (ROADMAP Randomised Olmesartan and Diabetes Microalbuminuria Prevention Study)

Desirable brands > Pricing Power > 5 major sectors

Only companies with a strong brand or unique know-how benefit from this ability to set their prices without impacting demand and thus preserve their margins.

Read more